Skip to main content
Premium Trial:

Request an Annual Quote

Rockland Immunochemicals Buys Line of Antibodies for Epigenetics Research

NEW YORK (GenomeWeb News) – Research reagents company Rockland Immunochemicals today said it has purchased the Epi-Plus antibody product line from 21st Century Biochemicals for an undisclosed amount.

Epi-Plus antibodies are used for epigenetics research and have been validated by multi-assay methods, including dot blot testing using modified peptide arrays, Western blots, and chromatin immunoprecipitation.

Rockland said that studies have indicated that epigenetic pharmaceuticals may be a putative replacement or adjuvant therapy for current methods such as radiation and chemotherapy and noted that the global market for epigenetics is estimated to reach $8 billion by 2017, compared to $2.6 billion in 2012.

Jim Fendrick, president and CEO of Rockland, said in a statement that the deal expands the firm's life science tools portfolio "and will allow our customers to perform their research in a more efficient and effective manner, ultimately saving time and precious research dollars." He also said that the Epi-Plus brand is co-owned by Novus Biologicals, which will allow Rockland to expand its brand worldwide.

In December Gilbertsville, Penn.-based Rockland purchased the Trueblot IP/Western blot product line from Affymetrix's eBioscience business.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.